1. Home
  2. AGPU vs BOLD Comparison

AGPU vs BOLD Comparison

Compare AGPU & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$5.59

Market Cap

36.8M

Sector

N/A

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.53

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGPU
BOLD
Founded
2002
2018
Country
United States
United States
Employees
14
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
36.8M
36.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
AGPU
BOLD
Price
$5.59
$1.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
3.8M
402.4K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12,476.23
N/A
Revenue Next Year
$55.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.96
52 Week High
$10.86
$1.72

Technical Indicators

Market Signals
Indicator
AGPU
BOLD
Relative Strength Index (RSI) 56.63 65.14
Support Level $1.46 $1.08
Resistance Level $6.46 N/A
Average True Range (ATR) 0.89 0.09
MACD -0.01 -0.01
Stochastic Oscillator 32.21 57.14

Price Performance

Historical Comparison
AGPU
BOLD

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: